Dr. Ernst von Schwarz to Host Webinar: VesCell for Advanced Cardiac Conditions

May 5th, 12:00 p.m. Four published studies of 24, 41, 106, 54 subjects reviewed - treated for various forms of heart disease with VesCell.

CALGARY, ALBERTA — April 21, 2026 — Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”), commercializing VesCell - an autologous (patient’s own) angiogenic cell therapy - in The Bahamas and Florida, is pleased to announce Dr. Ernst von Schwarz and Dr. York N. Hsiang will host a live webinar: "When Standard Heart Treatment Isn't Enough.” The webinar is open to patients, caregivers, and members of the public who have an interest in the treatment of advanced cardiac conditions including ischemic cardiomyopathy, dilated cardiomyopathy, angina, and heart failure. Attendance is available by registration at May 5 Webinar

About the Presenters

Prof. Dr. Ernst von Schwarz is a triple board-certified cardiologist, transplant surgeon and stem cell scientist specializing in the treatment of advanced heart failure. He is Clinical Professor of Medicine at the University of California, Los Angeles (UCLA) and is the author of "The Secrets of Immortality." Dr. von Schwarz has published extensively in peer-reviewed journals on cardiovascular disease and stem cell research.

Dr. York N. Hsiang is a vascular surgeon with over three decades of clinical experience, and served as a Principal Investigator of the Phase II clinical trial of ACP-01. Professor of Vascular Surgery, Emeritus, Dr. Hsiang held academic appointments at the University of British Columbia and has contributed to numerous peer-reviewed publications on vascular disease management.

Management Commentary

"Patients with advanced cardiac disease are looking for results: stronger ejection fraction, longer distance on the 6-minute walk, fewer angina episodes, and fewer arrhythmias. This session cuts through the noise—directly and without dilution. Understand how and why VesCell autologous cell therapy changed outcomes in Angina, Ischemic and Dilated cardiomyopathy patients. My thanks to Dr. Ernst von Schwarz and Dr. York N. Hsiang for bringing first-hand clarity to a population and space that needs it.”— Thomas Smeenk, CEO.

About Hemostemix

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 40% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years. For more information, please visit www.hemostemix.com.

For further information, please contact: Thomas Smeenk, President, CEO EM: tsmeenk@hemostemix.com / PH: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the attendance of the Company’s webinar on May 5, 2026, the treatment of conditions of ischemia with Angiogenic Cell Precursors (ACP-01), in furtherance of sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale of treatments in Florida and The Bahamas. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.